Single molecule fluorescent sequencing

SeqLL Inc. Announces Closing of Underwriters’ Option to Purchase Additional Shares of Common Stock in Connection with its Initial Public Offering

Retrieved on: 
Wednesday, September 29, 2021
Molecule, Nature, Park Avenue, Exercise, Risk, Security (finance), Sale, NASDAQ, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Single molecule fluorescent sequencing, SQL, Form, Company, Disease, Technology, Research, NOS, Forward-looking statement, Intellectual property, Prospectus, Time, SEC, GLOBE

After giving effect to the exercise of the over-allotment option, the total gross proceeds of the initial public offering increased to approximately $13,810,950.

Key Points: 
  • After giving effect to the exercise of the over-allotment option, the total gross proceeds of the initial public offering increased to approximately $13,810,950.
  • Maxim Group LLC acted as the sole book-running manager in connection with the offering.
  • The offering was made only by means of a prospectus forming part of the effective registration statement.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SeqLL Announces Publication of a New Blood-Based RNA Sequencing Method to Detect Coronary Artery Disease

Retrieved on: 
Monday, September 27, 2021
Molecule, BioMed Central, Korea Disease Control and Prevention Agency, Nature, PCR, Coronary artery disease, Gene expression, Moyamoya disease, School, Risk, RNA, Regulation, Security (finance), Inova Health System, NASDAQ, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Atherosclerosis, DNA, GW, Patient, Death, CAD, Physician, Single molecule fluorescent sequencing, Independent school district, Biomarker, Gene, SQL, GLOBE, Bias, Form, Autoimmunity, Company, Cardiovascular disease, Disease, Genomics, Artery, COVID-19, Technology, RNA-Seq, Center, Research, George Washington University, Forward-looking statement, Diagnosis, Intellectual property, Washington, Cardiac catheterization, Doctor of Philosophy, Coronary CT angiography, CO, Pharmaceutical industry, Medical imaging, Vaccine

Diagnosis of CAD is typically based on coronary angiography, an imaging process used to detect restricted blood flow in the hearts major arteries.

Key Points: 
  • Diagnosis of CAD is typically based on coronary angiography, an imaging process used to detect restricted blood flow in the hearts major arteries.
  • Using SeqLLs tSMS platform, our team was able to sequence millions of RNA strands per patient at single molecule resolution.
  • This allowed us to reproducibly identify specific RNA transcripts that were altered in patients with coronary disease, Dr. McCaffrey said.
  • This study represents another step toward providing improved, non-invasive diagnostic options to those suffering from coronary artery disease.

Pacific Biosciences Grants Equity Incentive Award to New Employee

Retrieved on: 
Friday, September 24, 2021
Molecule, Pacific Biosciences, Biomedical Research, RSU, Financial compensation, NASDAQ, Single molecule fluorescent sequencing, Microbiology, Option, Effective date, Pacific Ocean, Genetic variation, GLOBE

MENLO PARK, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock, and restricted stock units (RSUs) covering 50,000 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the 2020 Inducement Plan) effective on September 20, 2021.

Key Points: 
  • MENLO PARK, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock, and restricted stock units (RSUs) covering 50,000 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the 2020 Inducement Plan) effective on September 20, 2021.
  • The options have an exercise price of $27.99 per share, which is equal to the closing price of Pacific Biosciences common stock on September 20, 2021 (the Effective Date).
  • The option grant and the award of restricted stock units are subject to the terms and conditions of the 2020 Inducement Plan and the award agreements entered into with the non-executive officer employee.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.

SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL’s tSMS® Platform

Retrieved on: 
Thursday, September 23, 2021
Molecule, National Human Genome Research Institute, Nature, Gene expression, RNA transfection, PCR, AML, National, Risk, RNA, NHGRI, Security (finance), Massachusetts, Hospital, NASDAQ, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, DNA, Single molecule fluorescent sequencing, User experience, Independent school district, SQL, Method, Lung cancer, Bias, CEO, Form, Company, Adenosine, Disease, Cell, Technology, Aichi M6A, Research, NIH, Forward-looking statement, Intellectual property, Doctor of Philosophy, Time, Massachusetts General Hospital, GLOBE, 3D printing, Pharmaceutical industry, Fine chemical

WOBURN, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the peer-reviewed publication of a new microscopy-based epitranscriptomic method powered by SeqLL’s tSMS platform in the August issue of Cell Report Methods. The method was developed in collaboration with the laboratory of Bradley E. Bernstein, MD, PhD through grant R01-HG009269 from the National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI).

Key Points: 
  • However, this platform provides multifaceted information in single cell resolution, which will be helpful for cancer diagnosis and assessing its causality.
  • Using this epitranscriptomic method to profile single cells, researchers will have the power to reveal insights into complex biological pathways beyond those that current methods allow.
  • SeqLLs exclusive True Single Molecule Sequencing (tSMS) technology enables direct sequencing of millions of individual molecules.
  • The tSMS platform offers maximum flexibility and avoids many of the challenges common for standard sequencing approaches.

SeqLL Inc. Announces Closing of Upsized $13 Million Initial Public Offering

Retrieved on: 
Tuesday, August 31, 2021
Molecule, Company, LLC, Nasdaq, U.S. Securities and Exchange Commission, Form, Nature, GLOBE, SEC, Research, NOS, Private Securities Litigation Reform Act, Disease, Risk, Independent school district, Time, Intellectual property, Forward-looking statement, SQL, NASDAQ, Prospectus, Single molecule fluorescent sequencing, Sale, Park Avenue, Technology, Security (finance)

All of the shares of common stock and warrants were being offered by the Company.

Key Points: 
  • All of the shares of common stock and warrants were being offered by the Company.
  • The shares of common stock and warrants began trading on the Nasdaq Capital Market on August 27, 2021, under the symbols SQL and SQLLW, respectively.
  • The Company intends to use substantially all of the net proceeds from the offering to expand its commercial operations to support life sciences research and applications development.
  • SeqLL Inc. (SeqLL) is a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple omics fields.

SeqLL Inc. Announces Pricing of Upsized $13 Million Initial Public Offering

Retrieved on: 
Friday, August 27, 2021
Molecule, Company, Nasdaq, U.S. Securities and Exchange Commission, Form, Nature, GLOBE, SEC, Research, NOS, Private Securities Litigation Reform Act, Disease, Risk, Independent school district, Time, Intellectual property, Forward-looking statement, SQL, NASDAQ, Prospectus, Single molecule fluorescent sequencing, Sale, Park Avenue, Technology, Security (finance)

In addition, SeqLL has granted the underwriters a 45-day option to purchase up to an additional 459,000 shares of common stock and/or warrants to purchase 459,000 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount.

Key Points: 
  • In addition, SeqLL has granted the underwriters a 45-day option to purchase up to an additional 459,000 shares of common stock and/or warrants to purchase 459,000 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount.
  • All of the shares of common stock and warrants are being offered by the Company.
  • The offering is expected to close on August 31, 2021, subject to satisfaction of customary closing conditions.
  • The offering is being made only by means of a prospectus forming part of the effective registration statement.